Lanean...
Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization
Oncolytic virotherapies, including the modified herpes simplex virus talimogene laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour immune effects. The OPTiM trial, in particular, demonstrated the superior anti-cancer effects of T-VEC as compared to systemic immunoth...
Gorde:
| Argitaratua izan da: | PLoS Comput Biol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Public Library of Science
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6880985/ https://ncbi.nlm.nih.gov/pubmed/31774808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pcbi.1007495 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|